Clinical Trials Logo

Poor Graft Function clinical trials

View clinical trials related to Poor Graft Function.

Filter by:
  • None
  • Page 1

NCT ID: NCT05907499 Not yet recruiting - Poor Graft Function Clinical Trials

Decitabine for Poor Graft Function Post Allo-HSCT

Start date: July 1, 2023
Phase: Phase 3
Study type: Interventional

This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.

NCT ID: NCT05669079 Not yet recruiting - Poor Graft Function Clinical Trials

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.

NCT ID: NCT03718533 Terminated - Poor Graft Function Clinical Trials

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

ELTION
Start date: December 17, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks after the initiation of eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

NCT ID: NCT03437603 Not yet recruiting - Poor Graft Function Clinical Trials

Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation

Start date: February 2018
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and safety for secondary poor graft function (PGF) post allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the hematologic response rate. Secondary objectives include: (1) incidence and severity of adverse events; (2) overall survival (OS), and disease-free survival(DFS).

NCT ID: NCT02240992 Recruiting - Clinical trials for Hematological Diseases

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor graft function or delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

NCT ID: NCT02083718 Recruiting - Clinical trials for Hematological Diseases

Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with Granulocyte Colony-Stimulating Factor (G-CSF) mobilized peripheral stem cell combined (PBSC) with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. Our first objective was to evaluate the effect of such treatment on poor graft function, and second object was to investigate the safety of such treatment.

NCT ID: NCT01857336 Completed - Clinical trials for Graft Versus Host Disease

G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation

Start date: March 1, 2013
Phase: N/A
Study type: Interventional

Poor graft function (PGF) is a common complication after allogeneic stem cell transplantation, which was associated with high mortality. The pathogenesis fo PGF was poorly understood. Infusion of donor peripheral cell harvest was effective for some patients with PGF in our preliminary study. This present study aimed to explore the efficacy of peripheral cell harvest for poor graft function.

NCT ID: NCT01763086 Recruiting - Clinical trials for Mesenchymal Stem Cells

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. Our first objective was to evaluate the effect of such treatment on poor graft function, and second object was to investigate the safety of such treatment.

NCT ID: NCT00603330 Recruiting - Clinical trials for Graft-versus-host Disease

Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD. Part 2: Poor graft function (PGF) Part 3: Low or falling donor T-cell chimerism after allogeneic HCT. This is a multicenter phase II study examining the feasibility and efficacy of this approach.